SARS-CoV-2 Seroprevalence among Healthcare, First Response, and Public Safety Personnel, Detroit Metropolitan Area, Michigan, USA, May-June 2020.
Adolescent
Adult
Aged
COVID-19
/ blood
COVID-19 Serological Testing
Emergency Responders
/ statistics & numerical data
Female
Health Personnel
/ statistics & numerical data
Humans
Male
Michigan
/ epidemiology
Middle Aged
Pandemics
/ statistics & numerical data
Personal Protective Equipment
/ statistics & numerical data
SARS-CoV-2
/ isolation & purification
Seroepidemiologic Studies
Surveys and Questionnaires
Young Adult
2019 novel coronavirus disease
COVID-19
Detroit
SARS-CoV-2
coronavirus disease
emergency responders
hospitals
personal protective equipment
public safety
seroepidemiologic studies
severe acute respiratory syndrome coronavirus 2
viruses
zoonoses
Journal
Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
pubmed:
22
9
2020
medline:
2
1
2021
entrez:
21
9
2020
Statut:
ppublish
Résumé
To estimate seroprevalence of severe acute respiratory syndrome 2 (SARS-CoV-2) among healthcare, first response, and public safety personnel, antibody testing was conducted in emergency medical service agencies and 27 hospitals in the Detroit, Michigan, USA, metropolitan area during May-June 2020. Of 16,403 participants, 6.9% had SARS-CoV-2 antibodies. In adjusted analyses, seropositivity was associated with exposure to SARS-CoV-2-positive household members (adjusted odds ratio [aOR] 6.18, 95% CI 4.81-7.93) and working within 15 km of Detroit (aOR 5.60, 95% CI 3.98-7.89). Nurse assistants (aOR 1.88, 95% CI 1.24-2.83) and nurses (aOR 1.52, 95% CI 1.18-1.95) had higher likelihood of seropositivity than physicians. Working in a hospital emergency department increased the likelihood of seropositivity (aOR 1.16, 95% CI 1.002-1.35). Consistently using N95 respirators (aOR 0.83, 95% CI 0.72-0.95) and surgical facemasks (aOR 0.86, 95% CI 0.75-0.98) decreased the likelihood of seropositivity.
Identifiants
pubmed: 32956614
doi: 10.3201/eid2612.203764
pmc: PMC7706918
doi:
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
2863-2871Références
J Microbiol Immunol Infect. 2021 Feb;54(1):54-60
pubmed: 32359943
Emerg Infect Dis. 2020 Sep;26(9):1978-1986
pubmed: 32544053
JAMA. 2020 Jun 16;323(23):2425-2427
pubmed: 32421144
JAMA Intern Med. 2020 Jul 21;:
pubmed: 32692365
Infect Control Hosp Epidemiol. 2020 Jul;41(7):765-771
pubmed: 32391746
BMC Health Serv Res. 2009 Jun 29;9:110
pubmed: 19563625
Lancet Infect Dis. 2020 May;20(5):565-574
pubmed: 32213337
J Clin Virol. 2020 Jul;128:104437
pubmed: 32434708
JAMA. 2020 Jul 14;324(2):195-197
pubmed: 32539107
Pediatr Allergy Immunol. 2020 Oct;31(7):841-847
pubmed: 32413201
MMWR Morb Mortal Wkly Rep. 2020 Aug 21;69(33):1122-1126
pubmed: 32817602
Am J Infect Control. 2017 May 1;45(5):542-543
pubmed: 28302435
Lancet. 2020 Aug 1;396(10247):313-319
pubmed: 32534626
Nat Med. 2020 Aug;26(8):1193-1195
pubmed: 32504052
Ann Epidemiol. 2020 Aug;48:23-29.e4
pubmed: 32648546
Emerg Infect Dis. 2020 Nov;26(11):2766-2769
pubmed: 32731911
Clin Infect Dis. 2020 Dec 17;71(10):2702-2707
pubmed: 32548613
Clin Infect Dis. 2020 Dec 17;71(10):2688-2694
pubmed: 32497196
Lancet Public Health. 2020 Sep;5(9):e475-e483
pubmed: 32745512
Health Aff (Millwood). 2020 Sep;39(9):1624-1632
pubmed: 32663045